Blog Category: Live

Livestream: The Force Awakens—Unlocking the Potential of IL-23–targeted Therapies in the Treatment of IBD

The therapeutic armamentarium for inflammatory bowel disease (IBD) is expanding with the advent of anti–IL-23 therapies. The unique clinical profiles of new and emerging agents make it necessary that treatment decisions are guided by evolving knowledge of the science surrounding …

The Force Awakens—Unlocking the Potential of IL-23–targeted Therapies in the Treatment of IBD

The therapeutic armamentarium for inflammatory bowel disease (IBD) is expanding with the advent of anti–IL-23 therapies. The unique clinical profiles of new and emerging agents make it necessary that treatment decisions are guided by evolving knowledge of the science surrounding …

The Life-long Care of Individuals with Lennox-Gastaut Syndrome: Strategies for Outcomes Optimization from Childhood Through Adulthood

Lennox-Gastaut syndrome (LGS) remains a challenging condition to understand, diagnose, and manage. Neuroscience/neurology clinicians, including nurses and nurse practitioners (NPs), encounter significant challenges in the management of patients with LGS, due to the severe symptoms and morbidities, diagnostic delays, and …

Livestream: The Life-long Care of Individuals with Lennox-Gastaut Syndrome: Strategies for Outcomes Optimization from Childhood Through Adulthood

Lennox-Gastaut syndrome (LGS) remains a challenging condition to understand, diagnose, and manage. Neuroscience/neurology clinicians, including nurses and nurse practitioners (NPs), encounter significant challenges in the management of patients with LGS, due to the severe symptoms and morbidities, diagnostic delays, and …

Livestream: IBD, IL-23, and Inflammation, Oh My! Following the Yellow Brick Road in Using IL-23 Targeted Therapies in Managing IBD

Significant therapeutic advancements have been made over the last decade for treatment of inflammatory bowel disease (IBD), a chronic condition that includes Crohn’s disease (CD) and ulcerative colitis (UC). The inflammatory cytokine interleukin (IL)-23 has been established as an active …

IBD, IL-23, and Inflammation, Oh My! Following the Yellow Brick Road in Using IL-23 Targeted Therapies in Managing IBD

Significant therapeutic advancements have been made over the last decade for treatment of inflammatory bowel disease (IBD), a chronic condition that includes Crohn’s disease (CD) and ulcerative colitis (UC). The inflammatory cytokine interleukin (IL)-23 has been established as an active …

Bridging Gaps and Advancing Care in Sickle Cell Disease in the Context of Drug Therapy

Sickle cell disease (SCD) is a pathology caused by a mutative hemoglobin protein that produces rigid, sickle-shaped red blood cells (RBCs). Lifelong complications of SCD include acute veno-occlusive crises (VOCs), whose recurrence takes a significant toll on patients, and end-organ …

Diagnostic and Therapeutic Advances in Primary Biliary Cholangitis: Maximizing Opportunities to Improve Patient Care and Outcomes

Primary biliary cholangitis (PBC) is a chronic autoimmune disease of the intrahepatic bile ducts that is often misdiagnosed until it progresses to advanced stages, including end-stage liver disease. Symptoms such as intractable pruritus and severe fatigue, often accompanied by abnormal …

Addressing Barriers in Advancing Equitable Biomarker Testing in Community Oncology

Biomarker and molecular testing to help oncologists match patients with the best cancer treatment can be challenging in the community oncology setting and in underserved communities. At present, patients with cancer in racially or ethnicly underserved communities are not receiving …